GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (STU:7NS0) » Definitions » Cyclically Adjusted PS Ratio

Palisade Bio (STU:7NS0) Cyclically Adjusted PS Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Cyclically Adjusted PS Ratio?

Palisade Bio does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Palisade Bio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Palisade Bio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Cyclically Adjusted PS Ratio Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
- - - -

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Palisade Bio's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Palisade Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Palisade Bio's Cyclically Adjusted PS Ratio falls into.



Palisade Bio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Palisade Bio does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Palisade Bio  (STU:7NS0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Palisade Bio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio (STU:7NS0) Business Description

Industry
Traded in Other Exchanges
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Palisade Bio (STU:7NS0) Headlines

No Headlines